Fluoroquinolone-Associated Risks

Tendonopathy Risk

The American Academy of Pediatrics notes that ciprofloxacin showed arthropathy rates of 21% in US populations versus 11% in comparators, with the study design unable to demonstrate non-inferiority for musculoskeletal safety 1, 2
Ciprofloxacin demonstrates intermediate risk for tendon complications 1, 2
The absolute increase in Achilles tendon rupture risk is approximately 12 cases per 100,000 persons within 90 days of fluoroquinolone treatment 3, 4
Current use increases the odds ratio for Achilles tendon rupture to 4.1 3, 4
Permanent discontinuation due to adverse events occurred in only 3.5% of patients treated with moxifloxacin 5

The American Academy of Pediatrics found that ciprofloxacin showed 3% neurologic adverse events versus 2% in comparators, with no clinically significant difference 1, 6

No specific citations are available for this section, as all relevant information was marked [ignore ref]

Patients over 60 years have 4 times higher risk of Achilles tendon rupture compared to the general population 3, 4
Concomitant corticosteroid use dramatically increases tendon rupture risk with an odds ratio of 43.2 3, 4
Renal dysfunction/failure increases tendon rupture risk 7
History of solid organ transplantation (kidney, heart, or lung) 6
Pre-existing tendon disorders including rheumatoid arthritis 6
Strenuous physical activity or sports participation 6, 3

Consider magnesium supplementation during fluoroquinolone treatment if no contraindications exist 4
Antioxidant supplementation with vitamin E or coenzyme Q10 may provide protective effects against tendon damage 4
Symptoms of tendinopathy typically occur within 1 week (median 6 days) but can appear as early as 2 hours or as late as 6 months after discontinuation 3, 4
Monitor for bilateral involvement, which occurs in more than half of cases 4